Financial Review: Intuitive Surgical (NASDAQ:ISRG) and Baird Medical Investment (NASDAQ:BDMD)

Baird Medical Investment (NASDAQ:BDMD) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Insider and Institutional Ownership

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 0.7% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Baird Medical Investment and Intuitive Surgical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	N/A	N/A	N/A	N/A	N/A
Intuitive Surgical	$8.35 billion	24.12	$2.32 billion	$7.56	74.34

Intuitive Surgical has higher revenue and earnings than Baird Medical Investment.

Volatility & Risk

Baird Medical Investment has a beta of -1.06, suggesting that its stock price is 206% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.

Profitability

This table compares Baird Medical Investment and Intuitive Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Intuitive Surgical	28.58%	15.08%	13.38%

Analyst Recommendations

This is a summary of current recommendations and price targets for Baird Medical Investment and Intuitive Surgical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1	0	0	0	1.00
Intuitive Surgical	1	8	16	2	2.70

Intuitive Surgical has a consensus target price of $611.08, suggesting a potential upside of 8.74%. Given Intuitive Surgical’s stronger consensus rating and higher possible upside, analysts clearly believe Intuitive Surgical is more favorable than Baird Medical Investment.

Summary

Intuitive Surgical beats Baird Medical Investment on 10 of the 11 factors compared between the two stocks.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.

About Intuitive Surgical

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.